World's First Dual Glucose-Ketone Sensor Gets CE Mark for Abbott
ABT is trading near its 52-week low of $81.97 (5.5% above the low).
Summary
Abbott Laboratories has secured CE Mark approval for its new dual glucose-ketone sensing technology, which is noted as the world's first. This regulatory clearance allows Abbott to market the innovative device for diabetes patients across Europe. The approval strengthens Abbott's position in the diabetes care market by introducing a differentiated product with a unique sensing capability.
At the time of this announcement, ABT was trading at $86.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $151B. The 52-week trading range was $81.97 to $139.06. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.